The Department of Health and Social Care’s newly released National Cancer Plan for England sets out a comprehensive agenda to improve cancer survival rates, reduce inequalities and modernise cancer services. For pharmacy professions working across hospital, primary care and integrated care systems, it represents a strategic blueprint that will directly influence workforce planning, digital infrastructure, medicines optimisation and commissioning priorities.

The plan echoes the themes of the NHS Long-Term Plan published in July 2025, which focused on early intervention, prevention, digital potential and tackling health inequalities. In broad terms, the cancer plan commits to earlier diagnosis, faster treatment pathways, accelerated access to innovation and stronger integration across care settings. It also positions cancer increasingly as a long-term condition, requiring ongoing medicines optimisation, not solely acute intervention.

As therapeutic complexity continues to grow with the use of systemic anti-cancer therapies (SACT), immunotherapies and precision medicines, pharmacy teams will play a central role with advanced prescribing capabilities. As the plan supports faster uptake of these innovative therapies, pharmacy teams will need to ensure safe adoption, horizon scanning, formulary decision-making and robust governance frameworks, alongside expanded clinical trial access.

Another theme the plan addresses is workforce. The plan recognises the need for specialist expertise to support increasingly complex treatments. The British Oncology Pharmacy Association (BOPA) has welcomed the plan, stating that cancer pharmacy professionals are “essential to delivering world-class cancer care” and highlighting their role in safe systemic therapy delivery, medicines optimisation, research and patient education. This reinforces the need to invest in advanced practice roles, prescribing capability and sustainable workforce pipelines to meet demand.

In general practice and primary care settings, the plan’s focus on integration and long-term management shifts cancer further into routine primary care activity. As more patients live longer with and beyond cancer, GP-based pharmacists will increasingly manage polypharmacy, treatment-related effects, and ongoing therapies. Earlier diagnosis targets will require strengthened medicines optimisation processes in primary care. For example, with the plan’s expansion of Community Diagnostic Centres as part of this earlier diagnosis focus, it should increase demand for timely medicines optimisation, rapid treatment initiation and coordinated pathway management by meeting the Faster Diagnosis Standard and improving performance against the 62-day referral-to-treatment target.

Digital transformation and interoperability are central to this shift. The plan references improving interoperability across prescribing systems to enable better information flow between primary, secondary and community settings. This reinforces the importance of integrated electronic prescribing, seamless medicines reconciliation and shared care documentation. The direction of travel is clear- cancer services must become more integrated, data-driven and prevention-focused.

The plan also places strong emphasis on reducing inequalities in access and outcomes. It highlights stark variation linked to deprivation, ethnicity and geography, noting that people in more deprived areas are significantly more likely to be diagnosed at a later stage and experience poorer outcomes. As a result, pharmacy leaders will need to consider how service design, clinical trial access and innovative medicines adoption can address variation across geographies and population groups and ensure equitable medicines access.

For pharmacy professionals, the plan offers both opportunity and challenge. At Clinical Pharmacy Congress in May, delegates can hear directly from BOPA as they deliver their insight on the National Cancer Plan and its implications for pharmacy, from policy to inclusive consultations. Join us 8-9 May in London to explore how pharmacy leadership, pathway redesign, workforce development and digital innovation can ensure the profession is prepared to deliver on these national ambitions.